Loading
  • Facebook
  • Instagram
  • Twitter
  • Reddit
  • LinkedIn
Dispense Magazine
  • Home
  • Articles
    • Featured
    • News
    • Health
    • Law
    • Interviews
  • Podcast
  • Resources
    • Physicians
    • Clinics
    • Dispensaries
    • Glossary
  • About
  • Contact
  • Advertise
  • Menu

Cannabis Science

Featured, Health, Science
Dispense Magazine - Cannabis ScienceDispense Magazine

The latest news, research, and reports on the therapeutic uses of cannabis from the scientific community.

Patient-Reported Symptom Relief Following Medical Cannabis Consumption

The Releaf Application continues to revolutionize the way studies are conducted. As a free App for patients, it is an invaluable tool for physicians, dispensaries and researchers to know exactly which products are alleviating exactly which conditions. A report in Frontiers of Pharmacology in August of last year detailed data from thousands of patients. This type of anonymous patient data provided much more accurate details on the positive and negative effects of medical cannabis.

The report said, “Since its release in 2016, the commercially developed Releaf AppTM application has been the only publically available, incentive-free patient educational software program designed for recording how individual cannabis usage sessions may correspond to immediate changes in primary symptom intensity levels and experienced side effects. This electronic assessment tool enables patients to monitor and manage their cannabis consumption decisions under naturalistic conditions while avoiding the limitations of retrospective survey collection methods (e.g., memory bias, social desirability effects).”

The study’s goal was “to calculate changes in patient-perceived symptom severity, the prevalence of positive and negative side effects associated with cannabis consumption, and whether the reported-effects differs depending on the symptom for which users were seeking treatment. We measured changes in symptom relief by subtracting the ending symptom level from the beginning
symptom (possible range from -10 to 10).“ “Conclusion: Patient-managed cannabis use is associated with clinically significant improvements in self-reported symptom relief for treating a wide range of health conditions, along with frequent positive and negative side
effects.”
www.frontiersin.org/articles/10.3389/fphar.2018.00916/full

TWO STUDIES ON CANNABIS AND PANCREATIC CANCER:

Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer

In January 2019, the Journal of Pancreatic Cancer published a literature review study of “the biological effects of cannabinoids in cancer treatment, with a focus on pancreatic cancer.” Pancreatic cancer, the study says, “is the fourth major cause of cancer death and is likely to become the second major cause of cancer death after lung cancer by 2030.” The authors looked at both “In vitro and in vivo studies that investigated the effects of cannabinoids in pancreatic cancer.”

This detailed study outlines all that is known on the endocannabinoid system through 2018, stating, “The bodies’ endogenous opioid and cannabinoid systems have remained unchanged for more than 500 million years of human evaluation. The endogenous cannabinoid system
contains endocannabinoids, cannabinoid receptors, second messengers, and anabolic and catabolic enzymes such as the fatty acid amide hydrolase (FAAH) system.”

Along with the CB-1 and CB-2 receptors, “there is a third putative human cannabinoid receptor, G-protein-coupled receptor 55 (GPR55). Studies have shown that malignant cells can alter the physiologic function of GPR55 and other GPCRs to enhance tumor growth and metastasis.”

The study goes into great detail on THC and CBD and their effects on cancer, the mechanisms of action, and the effects of cannabinoids on pancreatic cancer. One of the reviewed studies indicated, “the GPR55 receptor, regulated by tumor suppressor p53, may have a crucial role in pancreatic cancer development, via cell cycle regulation and MAPK signaling pathways. CBD binds to the GPR55 receptor and blocks its activity.”

The study concludes, “Endogenous cannabinoids, synthetic or cannabis extracted from plants, can reduce tumor invasion and growth, induce tumor cell death, and inhibit tumor angiogenesis via cannabinoid receptor or receptor-independent pathways. Cannabinoid receptors appear to be highly expressed in pancreatic cancer compared with normal pancreatic tissue. CBD and THC appear to have antiproliferative and proapoptotic effects. CBD in a clinically relevant pancreatic cancer model improved survival outcomes when combined with gemcitabine.” More research is, of course, needed “on the anticancer effects of various cannabinoid formulations, treatment dosing, [and] precise mode of action.”
www.ncbi.nlm.nih.gov/pmc/articles/PMC6352507

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer

In July 2019, Frontiers in Oncology published a study of “a new non-cannabinoid, non-psychoactive derivative of cannabis, termed FBL-03G, with the potential to treat pancreatic cancer.” The study had a very narrow focus – to test the therapeutic potential of FBL-03G and determine if it will “enhance radiotherapy during the treatment of pancreatic cancer.”

The study reports, “In vitro studies were first carried out with and without radiotherapy (RT). In vitro studies, in vivo studies were also conducted in small animals employing FBL-03G sustainably delivered from smart radiotherapy biomaterials, allowing continual exposure of the tumor to the cannabis derivative payloads over time.” “From the results of this study, the key findings include, the observation that a non-cannabinoid derivative of cannabis can enhance radiotherapy treatment outcomes in-vitro and in-vivo.”

The study outlined the materials and methods, including the FBL-03G synthesis, the Fabrication of Smart Radiotherapy Biomaterials (SRB) and the Mice and Generation of Syngeneic Pancreatic Cancer Models.

Results were presented in great detail as well, stating, “From the results of this study, the key findings include observation that a non-cannabinoid derivative of cannabis can enhance radiotherapy treatment outcomes in-vitro and in-vivo. Secondly, the sustained delivery of the cannabis derivative FBL-03G from smart radiotherapy biomaterials (SRBs) results in tumor growth inhibition of both locally treated and distant untreated tumors, with and without radiotherapy.”

The conclusion of this study is “a flavonoid derivative of cannabis demonstrates significant therapeutic potential in the treatment of pancreatic cancer, including radiosensitizing and cancer metastasis treatment potential. The results justify further studies to optimize therapy
outcomes toward clinical translation.”
www.ncbi.nlm.nih.gov/pmc/articles/PMC6663976

October 15, 2019/by Dispense Magazine
Tags: cannabinoids, Cannabis and Pancreatic Cancer, Cannabis Science, Flavonoid, medical cannabis, Medical Cannabis Magazine, Medical Cannabis News, medical marijuana, Pancreatic Cancer, ReLeaf, Releaf App, Releaf Application
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Reddit
  • Share by Mail
https://dispensemagazine.com/wp-content/uploads/2019/09/Cannabis-Science.jpg 720 1280 Dispense Magazine https://dispensemagazine.com/wp-content/uploads/2019/06/Dispense-Magazine-Logo-1.svg Dispense Magazine2019-10-15 15:01:582020-01-17 02:49:32Cannabis Science
You might also like
Dispense Magazine Podcast - How To Run A Patient-Focused DispensaryDispense Magazine How To Run A Patient-Focused Dispensary: An Interview with Victor Guadagnino, Jr.
Cannabis Terpenes, a guide for Medical Marijuana PatientsDispense Magazine Let's Talk Terpenes - Pinene
Dispense Magazine - A Message from Patrick K. Nightingale, Esq.Dispense Magazine A Message from Patrick K. Nightingale
Dispense Magazine When it comes to medical marijuana, relief can take many forms
State Denies Medial Marijuana Growing/Processing Company's Permit Renewal RequestDispense Magazine State denies medical marijuana growing/processing company’s permit renewal request
Standard Wellness Recalls Marijuana Drops - Dispense MagazineDispense Magazine Standard Wellness recalls medical marijuana drops

Featured

  • Cannabis Terpenes, a guide for Medical Marijuana PatientsDispense MagazineLet’s Talk Terpenes – FarnesolJanuary 20, 2020 - 10:50 pm
  • Cannabis Terpenes, a guide for Medical Marijuana PatientsDispense MagazineLet’s Talk Terpenes – CedreneJanuary 13, 2020 - 7:08 pm
  • Cannabis Terpenes, a guide for Medical Marijuana PatientsDispense MagazineLet’s Talk Terpenes – MentholJanuary 6, 2020 - 11:49 am
  • The PA Flower Shortage - Growing Pains or Structural Problems 3Dispense MagazineFlower Shortage in PA – Growing Pains or Structural Problems?January 5, 2020 - 3:06 pm
  • Dispense Magazine Podcast Now Available on iheartradioDispense MagazineDispense Podcast now available on iHeartRadioJanuary 1, 2020 - 5:21 pm
  • Cannabis Terpenes, a guide for Medical Marijuana PatientsDispense MagazineLet’s Talk Terpenes – FencholDecember 30, 2019 - 10:00 pm

Newsletter Signup

Download the Latest Issue!

Like us on Facebook

Follow us on Instagram

Dispense Magazine

800 Bay Ridge Ave

Apt 1
Pittsburgh, PA 15226

412.915.5340

[email protected]

Categories

  • Featured (68)
  • Health (81)
  • Interviews (26)
  • Law (10)
  • News (55)
  • Podcast (34)
  • Science (17)
  • Sponsored (7)
  • Terpenes (26)

Find Dispense Magazine

© 2019 - Dispense Magazine | Terms of Service | Privacy Policy | Cookies Policy | Disclaimer | Website by Budding Brand
  • Facebook
  • Instagram
  • Twitter
  • Reddit
  • LinkedIn
Let’s Talk Terpenes – Ocimene Cannabis Terpenes, a guide for Medical Marijuana PatientsDispense Magazine Cannabis Terpenes, a guide for Medical Marijuana PatientsDispense Magazine Let’s Talk Terpenes – Valencene Scroll to top

Dispense Magazine utilizes cookies to give you the best browsing experience possible. By continuing to browse the site, you are agreeing to our use of cookies.

OK


How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only

Enter your email address for a FREE digital copy of Dispense Magazine!

 

Enter your email address to receive this quarter’s issue, absolutely free!

If you would like a physical copy, please click here

Dispense Medical Marijuana Magazine Volume 1 Issue 3 Cover

Please fill out the form below, and we’ll send you a copy of our latest issue.

 

Dispense Medical Marijuana Magazine Volume 1 Issue 3 Cover

 

Enter your email address to receive this quarter’s issue, absolutely free!

If you would like a physical copy, please click here

This is text

2019 Multimedia Advertising Guide

Please fill out the form to receive a copy of our advertising guidelines. Once submitted, one of our advertising reps will get right back to you.